Alpha Tau Medical (NASDAQ:DRTS – Get Rating) had its target price lowered by research analysts at Piper Sandler from $19.00 to $12.00 in a note issued to investors on Wednesday, The Fly reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price target indicates a potential upside of 210.08% from the company’s previous close.
Alpha Tau Medical Price Performance
Shares of DRTS stock opened at $3.87 on Wednesday. The stock has a 50-day moving average of $4.77 and a 200-day moving average of $7.53. Alpha Tau Medical has a 1-year low of $3.75 and a 1-year high of $20.65.
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) last released its earnings results on Thursday, August 25th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.07. Research analysts expect that Alpha Tau Medical will post -0.73 earnings per share for the current year.
Institutional Inflows and Outflows
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTS)
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.